Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects
C Tang, T Godfrey, R Stawell, M Nikpour
INTERNAL MEDICINE JOURNAL | WILEY | Published : 2012
Due to multiple beneficial effects, including control of disease activity, reduction in cardiovascular events and improved survival, hydroxychloroquine is now recommended long-term for all patients with systemic lupus erythematosus. However, patients must be made aware of the possible risk of retinal toxicity and have eye examinations to monitor for this complication. As hydroxychloroquine becomes more widely used in systemic lupus erythematosus, physicians must also be aware of rare but serious adverse effects, including neuromyotoxicity and cardiotoxicity.
The University of Melbourne and St. Vincent's Hospital Melbourne Research Endowment Fund.We thank Dr Richard Stawell and Dr Daniel Polya for providing Figure 1. We also thank Dr Andrea Bendrups, Dr Rachael Knight and Dr Lyndell Lim for help with preparation of the manuscript. We acknowledge the support of St Vincent's Hospital Melbourne Research Endowment Fund, UCB Australia and GSK Australia, who provide financial support for lupus research at St Vincent's Hospital Melbourne.